CNTG - Centogene jumps 8% after Q3 top-line up 212% raises FY20 guidance

Centogene (CNTG) reports Q3 results:Revenues increased 212% Y/Y to €36.3M, driven by the continued expansion of our COVID-19 testing offering.Pharma revenues decreased 21%, while Clinical Diagnostics revenues (excl. COVID) decreased 25% compared to Q3 2019.Commercial COVID-19 testing contributed €27.4M in revenues in the quarter, up from €2.1M in Q2 2020.Cash flow used in operating activities of -€19.67M.Cash & cash equivalents of €28.8M.Segment adjusted EBITDA of €9.18M vs. €4.16M a year ago.FY20 guidance: Revenues guidance from €80M to greater than €100M.Shares are up 7.9% PM.

For further details see:

Centogene jumps 8% after Q3 top-line up 212%, raises FY20 guidance